JoelMorganrothMD

PubMed

• 7 citations
  Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.
  Lénaïg Tanneau, Mats O Karlsson, Susan L Rosenkranz, Yoninah S Cramer, Justin Shenje, Caryn M Upton, Joel Morganroth, Andreas H Diacon, Gary Maartens, Kelly E Dooley, ...> ;Clinical Pharmacology and Therapeutics. 2022 Oct 1
• 40 citations
  QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
  Kelly E. Dooley, Susan L. Rosenkranz, Francesca Conradie, Laura Moran, Richard Hafner, Florian von Groote-Bidlingmaier, Javier R. Lama, Justin Shenje, Jorge M. de los ...> ;The Lancet. Infectious Diseases. 2021 Feb 12
• 5 citations
  A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.
  Ofer Spiegelstein, Dorit Mimrod, Laura Rabinovich, Eli Eyal, Craig R Sprenger, Anna Elgart, Emil Samara, Joel Morganroth> ;Clinical Pharmacology in Drug Development. 2019 Jan 1
• 23 citations
  Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials
  Stephen C. Harris, Joel Morganroth, Steven R. Ripa, Michael D. Thorn, Salvatore V. Colucci> ;Postgraduate Medicine. 2017 Jan 4
• 10 citations
  Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.
  Joel Morganroth, Kristen K. Flaharty, Simona Parisi, Cecilia Moresino> ;Supportive Care in Cancer. 2016 Feb 1
• 2 citations
  Benefits of Centralized ECG Reading in Clinical Oncology Studies
  Robert Kleiman, Jeffrey Litwin, Joel Morganroth> ;Therapeutic Innovation & Regulatory Science. 2016 Jan 1
• 18 citations
  Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study
  Joel Morganroth, Yaning Wang, Michael D. Thorn, Yuji Kumagai, Stuart Harris, Norman Stockbridge, Robert Kleiman, Rashmi R. Shah> ;British Journal of Clinical Pharmacology. 2015 Sep 1
• 12 citations
  Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
  Joel Morganroth, Daniel D. Gretler, Stanley J. Hollenbach, Joseph L. Lambing, Uma Sinha> ;Expert Opinion on Pharmacotherapy. 2013 Jan 1
• Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.
  Morganroth, J.,Lepor, H.,Hill, L. A.,Volinn, W.,Hoel, G.> ;Clin. Pharmacol. Ther.. 2010 Mar 12
• 26 citations
  No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
  Ester Donado, Iñaki Izquierdo, Iñaki Pérez, Olga García, Rosa Mª. Antonijoan, Ignaci Gich, Anna Solans, Juana Peña, Joel Morganroth, Manuel J. Barbanoj> ;British Journal of Clinical Pharmacology. 2010 Apr 1
• 30 citations
  Evaluation and Management of Cardiac Safety Using the Electrocardiogram in Oncology Clinical Trials: Focus on Cardiac Repolarization (QTc Interval)
  Joel Morganroth, R R Shah, J W Scott> ;Clinical Pharmacology and Therapeutics. 2010 Feb 1
• 2 citations
  Proarrhythmic potential of reverse use-dependent drugs.
  Ihor Gussak, Jeffrey Litwin, Joel Morganroth> ;Journal of Electrocardiology. 2007 Sep 1
• 20 citations
  Eletrocardiographic monitoring in COPD patients receiving tiotropium.
  Joel Morganroth, Wolfgang Golisch, Steven Kesten> ;COPD. 2004 Aug 18
• 126 citations
  Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study
  Martin E. Stryjewski, Vivian H. Chu, William O'Riordan, Brian Warren, Lala M. Dunbar, D M Young, Marc Vallee, Vance G. Fowler, Joel Morganroth, Steven L. Barriere, Mic...> ;Antimicrobial Agents and Chemotherapy. 2006 Mar 1
• 64 citations
  A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
  Joel Morganroth, John P. DiMarco, Antonio Anzueto, Michael S. Niederman, Shurjeel Choudhri> ;Chest. 2005 Nov 1
• 50 citations
  Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy Subjects
  Steven L. Barriere, Fredric C. Genter, Elizabeth Spencer, Michael M. Kitt, David Hoelscher, Joel Morganroth> ;Journal of Clinical Pharmacology. 2004 Jul 1
• 56 citations
  Evaluation of vardenafil and sildenafil on cardiac repolarization.
  Joel Morganroth, Bernard Enno Ilson, Bonnie C. Shaddinger, Guissou A Dabiri, Bela Rajiv Patel, Duane A. Boyle, Venkat S. Sethuraman, Timothy H. Montague> ;The American Journal of Cardiology. 2004 Jun 1
• 40 citations
  A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment.
  Joel Morganroth> ;Journal of Electrocardiology. 2004 Jan 1
• 19 citations
  Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug development.
  Ihor Gussak, Jeffrey Litwin, Robert Kleiman, Scott Grisanti, Joel Morganroth> ;Journal of Electrocardiology. 2004 Jan 1
• 27 citations
  Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections
  Gerald A Faich, Joel Morganroth, Alan B Whitehouse, Jugroop S Brar, Peter Arcuri, Steven F Kowalsky, Daniel Haverstock, Roger A Celesk, Deborah A. Church> ;The Annals of Pharmacotherapy. 2004 May 1
• 64 citations
  Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.
  Nenad Sarapa, Joel Morganroth, Jean-Philippe Couderc, Steven F. Francom, Borje Darpo, Joseph C. Fleishaker, Janet D. McEnroe, William T. Chen, Wojciech Zareba, Arthur ...> ;Annals of Noninvasive Electrocardiology. 2004 Jan 1
• 31 citations
  Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parameters
  Jean-Philippe Couderc, Wojciech Zareba, Arthur J. Moss, Nenad Sarapa, Joel Morganroth, Borje Darpo> ;Journal of Electrocardiology. 2003 Dec 1
• 57 citations
  Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects
  Joel Morganroth, Peter Rüegg, Cornelia Dunger-Baldauf, Silke Appel-Dingemanse, Harald Bliesath, Martin Lefkowitz> ;The American Journal of Gastroenterology. 2002 Sep 1
• 33 citations
  Electrocardiographic effects of rivastigmine.
  Joel Morganroth, Stephen Graham, Richard Hartman, Ravi Anand> ;Journal of Clinical Pharmacology. 2002 May 1
• 4 citations
  The effect of terfenadine on the cardiac pharmacodynamics of sparfloxacin
  Joel Morganroth, Thomas Hunt, Mary Beth Dorr, David Magner, George H. Talbot> ;Clinical Therapeutics. 1999 Sep 1
• Join now to see all